<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01917825</url>
  </required_header>
  <id_info>
    <org_study_id>P12-06</org_study_id>
    <nct_id>NCT01917825</nct_id>
  </id_info>
  <brief_title>A Study of the Pharmacokinetics, Safety, and Preliminary Efficacy of MDT-15 in Subjects With Lumbosacral Radiculopathy</brief_title>
  <official_title>An Open-Label, Sequential, Dose Escalation Study of the Pharmacokinetics, Safety, and Preliminary Efficacy of MDT-15 in Subjects With Lumbosacral Radiculopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Spinal and Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Spinal and Biologics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this clinical trial are to investigate the pharmacokinetics and&#xD;
      safety of MDT-15 pellets in escalating sequential doses administered to different cohorts.&#xD;
      Preliminary efficacy data will also be collected for assessment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>84 days</time_frame>
    <description>The Pharmacokinetics profile (Cmax, Tmax, AUC0-t, and AUC0-∞) following administration of up to six MDT-15 pellets in escalating sequential doses to different cohorts will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>84 days</time_frame>
    <description>The Pharmacokinetics profile (Cmax, Tmax, AUC0-t, and AUC0-∞) following administration of up to six MDT-15 pellets in escalating sequential doses to different cohorts will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>84 days</time_frame>
    <description>The Pharmacokinetics profile (Cmax, Tmax, AUC0-t, and AUC0-∞) following administration of up to six MDT-15 pellets in escalating sequential doses to different cohorts will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>84 days</time_frame>
    <description>The Pharmacokinetics profile (Cmax, Tmax, AUC0-t, and AUC0-∞) following administration of up to six MDT-15 pellets in escalating sequential doses to different cohorts will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>364 days</time_frame>
    <description>Incidence of Adverse Events as a Measure of Safety.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Radicular Leg Pain</measure>
    <time_frame>Baseline and 364 days</time_frame>
    <description>Radicular leg pain measured by a 0-10 Numeric Rating Scale (NRS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Function</measure>
    <time_frame>Baseline and 364 days</time_frame>
    <description>Physical Functioning measured by the Modified Roland Disability Questionnaire (RMS-L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Back Pain</measure>
    <time_frame>Baseline and 364 days</time_frame>
    <description>Back pain measured by a 0-10 Numeric Rating Scale (NRS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neuropathic Type Symptoms</measure>
    <time_frame>Baseline and 84 days</time_frame>
    <description>Neuropathic Type Symptoms as measured by the Short-form McGill Pain Questionnaire (SF-MPQ-2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Medical Outcomes study - Sleep Scale</measure>
    <time_frame>Baseline and 84 days</time_frame>
    <description>Sleep as measured by the Medical Outcomes Study - Sleep Scale (MOS-Sleep).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Emotional Function</measure>
    <time_frame>Baseline and 84 days</time_frame>
    <description>Emotional functioning as measured by the Profile of Mood States - Brief Form (POMS- Brief).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Work Function</measure>
    <time_frame>Baseline and 84 days</time_frame>
    <description>Work Function as measured by the Work Limitations Questionnaire (WLQ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Rating of Improvement</measure>
    <time_frame>84 days</time_frame>
    <description>Global rating of improvement as measured by a Patient Global Impression of Change (PGIC).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Sciatica</condition>
  <condition>Lumbosacral Radiculopathy</condition>
  <arm_group>
    <arm_group_label>MDT-15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatments will be administered to separate, sequential cohorts of 18 treated subjects in the following escalating doses:1 pellet, 3 pellets, and 6 pellets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MDT-15</intervention_name>
    <arm_group_label>MDT-15</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be male or female at least 18 years of age.&#xD;
&#xD;
          2. Have radiating pain toward the buttock down to the leg and/or feet, unilateral.&#xD;
&#xD;
          3. Have radiologic pathology change from L1 - S1 consistent with a disc protrusion,&#xD;
             non-sequestered extrusion, or sequestered fragment, as evidenced by magnetic resonance&#xD;
             imaging (MRI), that is consistent with the clinical signs and symptoms of lumbar&#xD;
             radiculopathy. The MRI must have been performed within 2 months prior to screening or&#xD;
             it will need to be repeated.&#xD;
&#xD;
          4. Have primary leg pain with an average NRS score equal to or greater than 5 as measured&#xD;
             twice a day for five days in each of two weeks during screening.&#xD;
&#xD;
          5. Have failed conservative care for at least 6 weeks. The subject must have been treated&#xD;
             non-operatively (e.g., bed rest, physical therapy, medications, TENS, and/or&#xD;
             manipulation) for a period of at least 6 weeks.&#xD;
&#xD;
          6. Be willing to stop current anti-inflammatory therapy taken for treatment of radicular&#xD;
             pain.&#xD;
&#xD;
          7. Be willing and able to keep a diary that will record study-related information.&#xD;
&#xD;
          8. If sexually active female of childbearing potential, be willing to use an acceptable&#xD;
             method of birth control during the study. Acceptable methods include oral&#xD;
             contraceptives (the pill), IUDs, contraceptive implants under the skin, contraceptive&#xD;
             rings or patches or injections, diaphragms with spermicide, and condoms with&#xD;
             spermicide. Surgical sterilization by tubal ligation or hysterectomy is acceptable.&#xD;
             Women of child bearing potential are defined as women who are &lt;12 months since their&#xD;
             last menstrual cycle prior to screening and have not experienced surgical menopause.&#xD;
&#xD;
          9. Be able to understand the study and provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have a history of lumbar surgery, including vertebroplasty and kyphoplasty.&#xD;
&#xD;
          2. Be ≤ 6 weeks after lumbar ESI or nerve block at start of screening.&#xD;
&#xD;
          3. Have current radicular pain for more than 6 months.&#xD;
&#xD;
          4. Have more than one epidural steroid injection at the affected level to be treated&#xD;
             within the last 6 months.&#xD;
&#xD;
          5. Have demonstrated radiographic changes consistent with subject's symptoms at more than&#xD;
             one level on the baseline MRI.&#xD;
&#xD;
          6. Have symptomatic spinal stenosis of central origin at any level based on CT myelogram&#xD;
             or MRI.&#xD;
&#xD;
          7. Have pain that is localized in the lower back or other sites and is a greater&#xD;
             component of the subject's total pain than the pain in the lower leg and/or foot.&#xD;
&#xD;
          8. Have physical problems that may interfere with any study assessments.&#xD;
&#xD;
          9. Have known infection with human immunodeficiency virus, hepatitis B virus, or&#xD;
             hepatitis C virus.&#xD;
&#xD;
         10. Have presence of local or systemic malignant disease or history of local or systemic&#xD;
             malignant disease in the past 5 years (history of basal cell carcinoma will be&#xD;
             allowed).&#xD;
&#xD;
         11. Have impaired renal function (creatinine &gt;1.5 times upper limit of normal).&#xD;
&#xD;
         12. Have chronic impairment liver function (aspartate aminotransferase [AST] or alanine&#xD;
             aminotransferase [ALT] &gt;3 times upper limit of normal).&#xD;
&#xD;
         13. Have insulin-dependent diabetes or uncontrolled diabetes mellitus (glycosylated&#xD;
             hemoglobin [HbA1c] &gt;7%).&#xD;
&#xD;
         14. Have leukopenia (&lt;3,500 leukocytes/uL).&#xD;
&#xD;
         15. Have current orthostatic hypotension (defined as systolic blood pressure decrease of&#xD;
             at least 20 mmHg or a diastolic blood pressure decrease of at least 10 mmHg or an&#xD;
             increase in heart rate by 20 beats per minute within 3 minutes of standing).&#xD;
&#xD;
         16. Have clinically significant risk for hypotension (e.g., hypotension defined as&#xD;
             systolic reading &lt;90 mmHg and/or diastolic &lt;60 mmHg, hypovolemia, autonomic&#xD;
             neuropathy, or other medical conditions affected by changes in blood pressure).&#xD;
&#xD;
         17. Any clinically significant cardiovascular condition as evidenced by physical exam,&#xD;
             medical history and/or baseline electrocardiogram (ECG).&#xD;
&#xD;
         18. Have evidence of bradycardia as shown by heart rate of &lt;60 beats per minute via&#xD;
             screening ECG.&#xD;
&#xD;
         19. Have any poorly-controlled or serious medical condition, psychiatric illness, or&#xD;
             clinically significant laboratory value that, in the opinion of the investigator,&#xD;
             could compromise the safety of the subject or the scientific integrity of the study&#xD;
             (e.g., uncontrolled hypertension, autoimmune disease, or clinically relevant symptoms&#xD;
             of thyroid dysfunction).&#xD;
&#xD;
         20. Have cauda equina syndrome.&#xD;
&#xD;
         21. Have neurological deficits, as determined by the investigator, which would interfere&#xD;
             with the assessments required by the protocol.&#xD;
&#xD;
         22. Have been previously diagnosed with peripheral neuropathy.&#xD;
&#xD;
         23. Have vascular claudication, as determined by the investigator, which would interfere&#xD;
             with the assessments required by the protocol.&#xD;
&#xD;
         24. Have a history or evidence of bleeding disorder (e.g., hemophilia, disseminated&#xD;
             intravascular coagulation disorder [DIC], or thrombocytopenia [TCP])&#xD;
&#xD;
         25. Have greater than 3 mm spondylolisthesis at the affected level.&#xD;
&#xD;
         26. Have BMI greater than or equal to 40, or with any anatomic issues that may interfere&#xD;
             with placement of the MDT-15 pellets as noted by the Investigator.&#xD;
&#xD;
         27. Have a diagnosis of major depression.&#xD;
&#xD;
         28. Have sustained a vertebral or hip fracture within the last year.&#xD;
&#xD;
         29. Have known or suspected allergy or hypersensitivity to clonidine, lidocaine, contrast&#xD;
             media, opioids, any medication that may be given as part of the site's standard of&#xD;
             care related to the study drug implantation procedure, or any other medication that&#xD;
             may be given as treatment during the study.&#xD;
&#xD;
         30. Have a known or suspected allergy to polylactic acid (found in products such as Lupron&#xD;
             Depot®, Atridox®, some types of dermal fillers, and some types of sutures).&#xD;
&#xD;
         31. If female, be pregnant or breastfeeding, or desiring to become pregnant during the&#xD;
             trial.&#xD;
&#xD;
         32. Have taken an investigational drug or used an investigational device within the past&#xD;
             30 days or intending to use an investigational drug or device during the trial.&#xD;
&#xD;
         33. Have active alcoholism or drug dependency, as determined by the investigator&#xD;
&#xD;
         34. Be currently on worker's compensation or in litigation related to injury or medical&#xD;
             condition.&#xD;
&#xD;
         35. Be in circumstances which make it difficult to maintain a usual nighttime sleep&#xD;
             schedule (e.g., the subject works on an evening/night shift or otherwise has a work or&#xD;
             activity schedule which could confound or interfere with study assessments).&#xD;
&#xD;
         36. Have current treatment with any of the following medications:&#xD;
&#xD;
               1. Systemic corticosteroids (intranasal/inhaled steroids are acceptable).&#xD;
&#xD;
               2. Immunosuppressant therapy to treat autoimmune diseases (e.g., rheumatoid&#xD;
                  arthritis, multiple sclerosis, myasthenia gravis, systemic lupus erythematosus,&#xD;
                  sarcoidosis, focal segmental glomerulosclerosis, Crohn's disease, Behcet's&#xD;
                  Disease, pemphigus, and ulcerative colitis).&#xD;
&#xD;
               3. Oral or topical products that contain clonidine (e.g., Catapres).&#xD;
&#xD;
               4. Herbal supplements that contain yohimbine.&#xD;
&#xD;
               5. Anti-coagulant therapy (prophylactic aspirin at 81mg/day is acceptable). If&#xD;
                  applicable, aspirin therapy should be held before and after the study procedure&#xD;
                  based on the investigator's discretion.&#xD;
&#xD;
               6. Calcium channel blocker, digoxin, or beta-adrenergic blockers.&#xD;
&#xD;
         37. Have chronic use of opioids (including tramadol), defined as use 20 out of the last 30&#xD;
             days prior to study screening.&#xD;
&#xD;
         38. Have emotional or health concerns (in the judgment of the investigator) that may&#xD;
             compromise the safety of the subject, may make compliance difficult, or may confound&#xD;
             the reliability of information acquired in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Holy Cross Orthopedic Institute</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Millennium Pain Center</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Spine Group</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan St Francis Pain and Spine Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otrimed Clinical Research</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pain and Rehabilitation Specialists</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>July 30, 2013</study_first_submitted>
  <study_first_submitted_qc>August 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2013</study_first_posted>
  <disposition_first_submitted>April 19, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>April 19, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 20, 2017</disposition_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radicular pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radiculopathy</mesh_term>
    <mesh_term>Sciatica</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

